Drug-device combination solutions to address opioid abuse.
Integrated products that combine medications with connected devices and cloud technologies to address major gaps in standard drug delivery — such as lack of usage tracking, poor adherence, and unauthorized access. Their first solution targets opioid use disorder, aiming to ensure correct dosing, deter misuse, and provide actionable data to clinicians and caregivers
TECHNOLOGY / INNOVATION
Core technology pairs pharmaceutical doses with smart devices and cloud-based tracking, enabling clinicians to monitor actual patient usage, record adherence data, and automatically control dose timing and access — ensuring the “right dose at the right time” while preventing diversion or accidental ingestion.
CURRENT STATUS
Final stages of gaining FDA clearance.
ORIGINS
Technology entrepreneur recognized the potential of technology to manage the distribution of addictive substances with a smart pill bottle.
OWNERSHIP
Privately held by founder and small group of private investors.
USP
USP lies in transforming passive prescriptions into active, monitorable therapies — combining medication delivery with behavioral-design, real-time usage tracking, and enforced dosing control. This reduces non-adherence, misuse, and safety risks — particularly relevant for opioid treatment and complex chronic regimens.
CUSTOMERS
Payers and insurance companies are highly motivated to keep high risk and high cost patience medication compliant. Physicians are motivated to reduce their liability for substance abuse by patients. Families highly motivated to keep their loved ones on the recovery path.
OF NOTE
Expecting FDA Clearance in early 2026
CEO
Matthew Ervin
MEDIA
